Swiss voters force boardroom pay controls
This article was originally published in Clinica
Swiss voters have shown overwhelming support for greater shareholder control over director and executive pay decisions. In a referendum shepherded to the public by Swiss businessman and independent MP Thomas Minder, 68% of the votes on Sunday 3 March were in favour of his proposals.
You may also be interested in...
The best-seller rankings today are testament to the great success of antibody drug technology developed at the end of the last century, and contrast with the dominance of primary care small molecule drugs that powered big pharma in previous decades. But where did these drugs come from – and where are they going?
Novartis is to acquire the Phase III siRNA drug inclisiran in a cash deal that swells its cardiovascular portfolio. The move will not be welcomed by Amgen, Sanofi or Regeneron.
Alliance with Molecular Templates may help advance efforts under Vertex’s existing collaboration with CRISPR Therapeutics. Dragonfly’s latest partner for its TriNKET platform is AbbVie.